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Background: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are heterogeneous with respect to biological
behaviour and prognosis. As angiogenesis is a renowned pathogenic hallmark as well as a therapeutic target, we aimed to
investigate the prognostic and clinico-pathological role of tissue markers of hypoxia and angiogenesis in GEP-NETs.
Methods: Tissue microarray (TMA) blocks were constructed with 86 tumours diagnosed from 1988 to 2010. Tissue microarray
sections were immunostained for hypoxia inducible factor 1a (Hif-1a), vascular endothelial growth factor-A (VEGF-A), carbonic
anhydrase IX (Ca-IX) and somatostatin receptors (SSTR) 1–5, Ki-67 and CD31. Biomarker expression was correlated with clinico-
pathological variables and tested for survival prediction using Kaplan–Meier and Cox regression methods.
Results: Eighty-six consecutive cases were included: 51% male, median age 51 (range 16–82), 68% presenting with a pancreatic
primary, 95% well differentiated, 51% metastatic. Higher grading (P¼ 0.03), advanced stage (Po0.001), high Hif-1a and low SSTR-2
expression (P¼ 0.03) predicted for shorter overall survival (OS) on univariate analyses. Stage, SSTR-2 and Hif-1a expression were
confirmed as multivariate predictors of OS. Median OS for patients with SSTR-2þ /Hif-1a-tumours was not reached after median
follow up of 8.8 years, whereas SSTR-2-/Hif-1aþ GEP-NETs had a median survival of only 4.2 years (P¼ 0.006).
Conclusion: We have identified a coherent expression signature by immunohistochemistry that can be used for patient
stratification and to optimise treatment decisions in GEP-NETs independently from stage and grading. Tumours with preserved
SSTR-2 and low Hif-1a expression have an indolent phenotype and may be offered less aggressive management and less stringent
follow up.
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are
tumours of unknown aetiology with heterogeneous biological
behaviour and prognosis. Although initially thought to be
uncommon, the incidence and prevalence of NETs are increasing
at a rate of 3–10% per year (Yao et al, 2008). The majority of
patients with NETs present with metastatic disease, the commonest
site being the liver. However, unlike all other gastrointestinal
malignancies, patients with stage IV disease may enjoy fairly
extended overall survival (OS) times, with median OS times
approaching 33 months (Yao et al, 2008).
The prognostic assessment of GEP-NETs can be further
refined by the use of the World Health Organization (WHO)
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tumour grading system, which sub-classifies patients according to
the degree of histological differentiation based on the prolife-
rating fraction of NET cells (Hirabayashi et al, 2013). However,
the natural biology of some GEP-NETs is such that there is
significant variation in prognosis within each stage and grade
subclass such that a proportion of patients will have a relative
indolent course with a long OS in the absence of any clinical
intervention. These patients may therefore receive treatment
unnecessarily, being exposed to significant side effects without
therapeutic benefit. Therefore, there is a need for more accurate
prognostic markers in order individualise therapy in this
otherwise very heterogeneous disease. Angiogenesis, the forma-
tion of new blood vessels from existing vasculature, is crucial in
tumour progression both in terms of local invasion and
metastatic spread (Hanahan and Weinberg, 2000). Normal
endocrine tissues and endocrine-derived tumours are highly
vascular, and numerous studies have shown a pathogenic role for
the overexpression of vascular endothelial growth factor (VEGF)
and other specific endothelial cell mitogens such as endocrine
gland-derived VEGF (EG-VEGF) in these tumours (LeCouter
et al, 2001; Katoh, 2003). The hypervascular nature of GEP-NETs
has been exploited as a therapeutic target, and the clinical
effectiveness of sunitinib, which in part relates to its anti-
angiogenic properties, has encouraged the clinical investigation of
novel anti-angiogenic agents in the management of these tumours
(Raymond et al, 2011).
Although the therapeutic relevance of angiogenesis is estab-
lished in GEP-NETs, inconsistent results have emerged as to its
prognostic role, mainly as previous studies have considered
individual angiogenic markers as predictors of outcome rather
than investigating the interplay between the various molecular
actors that drive the hypoxic response (Chi et al, 2006). Although
the adverse prognostic value of enhanced VEGF expression has
been shown in some studies (Zhang et al, 2007), others report
conflicting results with higher microvascular density and VEGF
expression predicting for a more favourable outcome (Couvelard
et al, 2005). In cancer, hypoxia inducible factors (Hif) regulate the
expression of a number of genes that stimulate tumour cell
proliferation in conditions of low oxygen tension, ultimately
promoting angiogenesis, local invasion and metastasis. Under
normal conditions, the Hif-1a subunit is hydroxylated by proline
hydroxylase in a reaction requiring oxygen and undergoes
ubiquitination by the von Hippel-Lindau (VHL) protein and is
then rapidly degraded in the proteasome (Giatromanolaki and
Harris, 2001). Under conditions of hypoxia, Hif-1a cannot be
degraded and accumulates in the nucleus, leading to enhanced
transcription of numerous hypoxic-response genes, such as VEGF,
EG-VEGF and carbonic anhydrase IX (Ca-IX) (Hui et al, 2002;
Maynard and Ohh, 2005).
Somatostatin receptors (SSTR) have been recognised as dynamic
regulators of tumour development, cell proliferation and apoptosis
(Ruscica et al, 2012). Somatostatin secretion is known to negatively
influence VEGF production (Mentlein et al, 2001), and in vitro
work has shown that the administration of the somatostatin
analogue octreotide can antagonise Hif-1a transcriptional activity
in NET cells (Villaume et al, 2010). Moreover, SSTR-2 expression
has been shown to have an anti-angiogenic role in animal models
of hypoxia (Dal Monte et al, 2007), suggesting an active interplay
between the somatostatin-signalling network and sustained
angiogenesis.
We designed this study to investigate the prognostic role
of a panel of immunohistochemical markers of hypoxia and
angiogenesis using tissue microarray (TMA) technology on a
consecutive series of patients presenting with GEP-NETs.
We compared the prognostic utility of these markers with other
more established prognostic determinants including tumour
staging and grading.
MATERIALS AND METHODS
Patient population. A total of 88 consecutive patients who
underwent surgical treatment for GEP-NETs at Imperial College
NHS Trust from 1988 to 2010 were included. Formalin fixed,
paraffin-embedded specimens and matching haematoxylin and
eosin (H&E) slides were retrieved from the local pathology archive.
Complete clinical and follow-up information including patient’s
demographics, tumour size and stage at diagnosis, site of
presentation were retrieved by review of medical records. The
presence of adverse pathological features such as vascular invasion
and necrosis were identified following H&E slides review
by a board certified endocrine pathologist (RD). Overall
(cancer-specific) survival was calculated from the time of surgery
to the time of death or last follow-up appointment. The study was
approved by the local Ethical Committee and conducted in
accordance to the principles of the Declaration of Helsinki. Serum
levels of chromogranin A (CgA) at diagnosis was retrieved
whenever available.
Tissue microarrays and immunohistochemistry. After review of
H&E-stained sections, three 1mm cores were identified from the
most representative areas of the tumour tissue, then re-embedded
into recipient TMA blocks using an MTA-1 Manual Tissue
Microarrayer (Beecher Instruments, Sun Prairie, WI, USA). Five-
mm-thick TMA sections were deparaffinised in xylene and
rehydrated in graded alcohols. Optimal heat-mediated antigen
retrieval conditions were applied according to the primary
antibody using a microwave oven at 900W. Incubation in citrate
buffer at pH 6.0 for 20min was preferred for antibodies VEGF-A
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), Hif-1a (Abcam,
Cambridge, UK), SSTR- 1–5 (Gramsch Laboratories, Schwabhausen,
Germany) CD31 and Ki-67 (Leica Microsystems, Wetzlar,
Germany), whereas antibodies to Ca-IX (Novus Biologicals,
Littleton, CO, USA) were incubated in pH 9.0 EDTA buffer for
30min. Before immunostaining, slides were cooled at room
temperature and endogenous peroxidase activity was suppressed
by incubation with a 3% solution of H2O2 for 5min. The primary
antibody against Ki-67 was diluted to 1 : 800, whereas all the other
antibodies were used at a 1 : 1000 dilution (Pinato et al, 2012b).
Tissue microarray slides were then stained through a
fully automated procedure on a Bond Max Autostainer (Leica
Microsystems) using the Polymer-HRP system (BioGenex, Fre-
mont, CA, USA) with subsequent development in diaminobenzi-
dine and Mayer’s haematoxylin counterstaining. Appropriately
selected tissue sections were used according to the manufacturer’s
instruction as external positive control during each reaction.
Negative control reactions were performed omitting the primary
antibodies from the dilution buffer. This resulted in a complete
absence of staining in all cases. Two trained histopatho-
logists (RD and NN) blinded to the clinical data scored all the
cases and a consensus score was reached in any case of
discrepancy. Tissue samples were scored manually using the
immunohistochemical score method (IHS), as described previously
(Pinato et al, 2012b). Briefly, each sample can be assigned an IHS
ranging between 0 and 300, based on the multiplication of the
percentage of cells showing immunohistochemical expression (0–100)
by the intensity of the signal (graded 1–3). Every core was assessed
individually and the mean of the three readings was calculated per
every single case. The pattern of staining (cytoplasmic, membranous,
nuclear and diffuse) was also described in each case.
Statistical analysis. The association between IHS and clinical-
pathological data of the patient cohort were determined by means
of w2, Fisher’s exact test or one-way ANOVA as appropriate. For
the purpose of analysis, the expression of each biomarker was
categorised as high vs low based on the median value of the
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distribution of IHS across the whole study population. The Ki-67-
labelling index was expressed as the fraction of positive nuclei
examining a minimum of 500 nuclei in at least five microscopic
fields as previously described (Pinato et al, 2012a). The Kaplan–
Meier statistics and Log-rank test were used to study the impact of
the different clinical factors associated with OS on univariate
analysis, with significant variables (Po0.05) being further tested
on a multivariate stepwise backward Cox regression model to
validate their independent prognostic value. An entry threshold of
0.05 was used at each step of the multivariate analysis, whereas
variables with a P-value 40.10 were removed from the model.
Variables emerging as independent predictors of survival at the last
step of the multivariate model were taken as significant if the
correspondent P-value waso0.10. For all the other statistical tests
a P-value o0.05 was taken to be significant. All statistical analysis
was conducted using SPSS statistical package 11.5 (SPSS Inc.,
Chicago, IL, USA).
RESULTS
Clinico-pathological profile of patients. The baseline patient
characteristics are shown in Table 1. Eighty-eight patients were
identified. Clinical data were missing on two patients and they
were excluded from subsequent analysis. The majority of clinical
samples included in our study were composed of primary NET
specimens (76/86, 88%), followed by seven liver metastatic deposits
and three lymph node metastases. All patients had undergone
radical resection of their GEP-NETs including excision of the
primary tumour associated with concurrent lymphadenectomy
and/or partial hepatectomy according to stage. The median age of
the patients at the time of diagnosis was 51 years (range 16–82).
The majority of patients were male (53%), and had a primary
pancreatic NET (n¼ 55), 34% of which were functional. Functional
tumours were mainly insulinomas (27%). Tumours were largely
sporadic, with only five cases emerging in the context of Multiple
Endocrine Neoplasia type 1. Forty-five patients (53%) presented
with metastatic disease, the commonest site of metastases being the
liver (73%) followed by locoregional spread to the lymph nodes
(27%). The majority of cases had well-differentiated tumours
(95%). The median tumour size was 30mm (range 6–125mm).
Necrosis was present in 12 (17%) of specimens and vascular
invasion in 20 (23%). Nineteen patients (22%) had a Ki-67-
labelling index 41%.
World Health Organization grading was obtained in all cases
and was scored as G1 in 84%, G2 in 13% and G3 in 4%. The
circulating plasma level of CgA at the time of diagnosis was
available for 27 patients (31%), with mean value of 178 mg l 1.
Plasma CgA levels 4100 mg l 1 correlated with the presence of
liver metastases (P¼ 0.02). No association was observed between
baseline CgA levels and survival. The median OS at the time of
analysis was 8.8 years (range 0.04–13.5 years).
Immunostaining in GEP-NETs and survival. The expression of
the studied biomarkers is summarised in Table 1. The pattern of
immunostaining was predominantly diffuse (cytoplasmic and
nuclear) for Hif-1a, cytoplasmic for VEGF-A and membranous
for SSTR-2 and Ca-IX (Figure 1). Somatostatin receptor-5
expression was cytoplasmic, whereas SSTR-1 was predominantly
nuclear and SSTR-3 was diffuse. The median IHS value for Hif-1a
was 200 (range 0–300), with elevated Hif-1a expression being
strongly associated with VEGF-A immunopositivity (Po0.001).
Median VEGF-A IHS was 240 (range 0–300), whereas median
Ca-IX IHS was 36 (0–300). High tissue expression levels of Hif-1a
and VEGF-A were associated with the presence of liver metastases
both from the pancreatic and gut primaries (Po0.05).
Table 1. General characteristics of the patient population
Baseline characteristic n¼86 (%)
Gender
Male 46 (53)
Female 40 (47)
Age, years
o55 48 (56)
X55 38 (44)
Primary site
Midgut 31 (36)
Pancreas 55 (64)
Tumour size, cm
o3.0 54 (63)
X3.0 28 (32)
Unknown 4 (5)
Stage
Limited disease 40 (47)
Loco regional lymph nodal spread 12 (14)
Metastatic disease 33 (39)
Unknown 1 (1)
Functional status
Non-functioning 56 (65)
Functioning 30 (35)
Insulinoma 23 (27)
Gastrinoma 7 (8)
Tumour necrosis
Absent 70 (78)
Present 12 (17)
Unknown 4 (5)
Angioinvasion
Absent 62 (72)
Present 20 (23)
Unknown 4 (5)
Chromogranin A at presentation
o100 mg l1 20 (23)
4100mg l 1 7 (8)
Unknown 59 (69)
Grading (WHO 2010 criteria)
Low 72 (84)
Intermediate 11 (13)
High 3 (3)
SSTR expression, low/high
SSTR-1 75/11 (87/13)
SSTR-2 61/25 (71/29)
SSTR-3 84/2 (98/2)
SSTR-4 86/0 (100/0)
SSTR-5 86/0 (100/0)
Angiogenesis biomarker expression, low/high
Hif-1a 41/45 (48/52)
VEGF-A 24/62 (28/72)
Carbonic anhydrase IX 77/9 (89/11)
CD31 86/0 (100/0)
Abbreviations: Ca-IX¼ carbonic anhydrase IX; Hif-1a¼ hypoxia inducible factor alpha;
SSTR¼ somatostatin receptor; VEGF¼ vascular endothelial growth factor-A; WHO¼World
Health Organization.
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The median IHS for SSTR-1 was 9 (range 0–300), SSTR-2
median 100 (range 0–300), SSTR-3 0 (range 0–240) and SSTR-5 0
(range 0–90). The entire case series profiled was negative for both
CD31 and SSTR-4 expressions.
In terms of the differing tumour types, pancreatic tumours
demonstrated a higher expression of SSTR-2 (Po0.01) and a trend
was observed for higher expression of SSTR-1 (P¼ 0.06). Hypoxia
inducible factor 1a was more highly expressed in carcinoid
Figure 1. Expression of the candidate biomarkers in GEP-NETs by immunohistochemistry. Representative sections of tumours showing positive
cytoplasmic staining for VEGF-A (A) and Hif-1a (B) showing a typical diffuse granular expression pattern. (C) Illustrates strong Ca-IX expression
within the neuroendocrine tumour cell membrane. (D) Shows a case of positive Ki-67 immunostaining in a high-grade neuroendocrine tumour.
(E–H) show somatostatin receptor expression in GEPNETs, with a typical nuclear pattern in SSTR-1 (E), a strong membranous expression for
SSTR-2 (F) followed by a predominant cytoplasmic immunolabelling for SSTR-3 and SSTR-5 expressions seen in (G and H), respectively.
Magnification 400.
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Figure 2. Kaplan–Meier curve analysis showing that advanced tumour stage (A), lack of SSTR-2 expression (B) and high Hif-1a expression (C)
predict for shortened OS in GEPNETs.
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tumours compared with pancreatic tumours (P¼ 0.05). In terms of
tumour characteristics, a significant association was observed
between KI-67 and tumour size (Po0.001) and the presence of
necrosis (P¼ 0.03).
The prognostic value of each biomarker was tested together with
established prognostic factors. Univariate analyses revealed the
following variables predicted for poor OS: advanced tumour stage
(P¼ 0.007) (Figure 2A), high WHO grading (P¼ 0.03), SSTR-2
expression loss (P¼ 0.03) and Hif-1a overexpression (P¼ 0.03).
Multivariate analysis of survival confirmed tumour stage
(P¼ 0.008), low SSTR-2 (P¼ 0.05) and elevated Hif-1a expression
(P¼ 0.06) as independent predictors of OS (Table 2). Median OS
for patients with SSTR-2-negative tumours was 5.7 years (95% CI
3.9–7.5) compared with 10.3 months (95% CI 0.3–20.4, Log-rank
P¼ 0.03) of the SSTR-2 positive cases (Figure 2B). Patient with
Hif-1a overexpressing tumours had a median OS of 5.8 years (95%
CI 3.6–7.9) compared with 9.6 median OS (95% CI 5.2–14.0, Log-
rank P¼ 0.03) of samples with low Hif-1a expression (Figure 2C).
On the basis of the results of the multivariate screening of
prognostic biomarkers, we combined Hif-1a overexpression and
SSTR-2 expression loss as individual categories with equal
weighting to devise a composite prognostic signature. Briefly,
patients received a score of 1 for either SSTR-2 loss or Hif-1a
overexpression, resulting in a model with three different the
prognostic strata (0, 1 and 2). Median survival for patients with a
score of 0 was not reached over a median follow up time of 8.8
years. Patients with a score of 1 had a median OS of 9.5 years (95%
CI 5.0–14.0), whereas patient allocated a score of 2 had a median
OS of only 4.2 (95% CI 2.1–6.3, Log-rank P¼ 0.006) (Figure 3).
When tested on an independent multivariate Cox regression model
using a backwards elimination approach, the newly devised
prognostic signature predicted for patients’ OS with a multivariate
hazard ratio (HR) of 2.3 (95% CI 1.0–5.4, P¼ 0.04), independently
from tumour stage (HR 2.3, 95% CI 1.1–5.4, P¼ 0.04) and WHO
grading (P¼ 0.23).
DISCUSSION
Prediction of the biological behaviour of NETs is currently based
on tumour cell differentiation and Ki-67 as a marker of
proliferation (Kloppel, 2011). These are not always reliable markers
of prognosis and there is an acute need for better prognostic
markers. As endocrine tumours are highly vascular, markers of
angiogenesis and its drivers warrant investigation in terms of their
prognostic significance. In this paper, we evaluated selected
biomarkers of hypoxia and angiogenesis together with SSTR
expression in a consecutive, unselected series of GEP-NETs.
We have identified a novel immunohistochemical expression
signature emerging from the multivariate screening of prognostic
Table 2. Clinico-pathological predictors of overall survival
Overall survival
Univariate analysis Multivariate analysis
Variable N¼86 Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Tumour stage
Locoregional/metastatic 38/30 7.8 (1.7–34.9) 0.007* 7.4 (1.7–33.0) 0.008#
Grading (WHO)
Low/intermediate/high 68/11/3 2.0 (0.4–11.0) 0.03*
Necrosis
Absent/present 70/12 2.1 (0.78–5.9) 0.12
Angioinvasion
Absent/present 62/20 1.5 (0.6–3.4) 0.33
SSTR-1 expression
Low/high 71/11 0.3 (0.0–2.4) 0.27
SSTR-2 expression
Low/high 61/25 0.21 (0.05–0.9) 0.03* 0.3 (0.07–1.4) 0.05#
Hif-1a expression
Low/high 41/45 2.7 (1.1–6.6) 0.03* 2.3 (1.0–5.7) 0.06#
VEGF-A expression
Low/high 24/62 1.2 (0.4–3.7) 0.69
Ca-IX expression
Low/high 77/9 0.4 (0.5–2.9) 0.39
Abbreviations: Ca-IX¼ carbonic anhydrase IX; Hif-1a¼hypoxia inducible factor alpha; SSTR¼ somatostatin receptor; VEGF¼ vascular endothelial growth factor-A; WHO¼World Health
Organization. Associations reaching statistical significance (Po0.05) are marked with an asterisk (*). Variables emerging as independent predictors of survival at the last step of the stepwise
regression Cox model were considered significant if the corresponding P-value was o0.10 and marked with an ash (#).
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tissue biomarkers using a TMA approach. We show that the
combined expression status of SSTR-2 and Hif-1a can shape a
three-tiered prognostic system with a highly significant difference
in median survival times for each category of patients. Interest-
ingly, the prognostic power of the expression signature is
independent from other commonly used predictors of outcome
such as tumour staging or grading.
Somatostatin receptor signalling pathways can promote a wide
range of downstream effects in GEP-NETs including inhibition of
cell secretion and growth through the modulation of mitogen-
activated protein kinase (MAPK) signalling or induction of
apoptosis (Patel and Srikant, 1997). Our study reproduces the
observation made by Kim et al (2011), where SSTR-2 expression
predicted for better survival outcomes in a large series of GEP-
NETs. This finding may be a reflection of tumour grade, with loss
of SSTR-2 expression being a feature of less-differentiated tumours,
mirroring the association between the lack of uptake of
radiolabelled somatostatin analogues in poorly differentiated
tumours (Ezziddin et al, 2006).
The relevance of SSTR-2 expression may, however, extend
beyond its prognostic value in GEP-NETs and may potentially
influence the use of somatostatin analogue therapy. The somato-
statin analogue octreotide binds preferentially to SSTR-2 (Kim
et al, 2011). Previous studies have shown that octreotide
administration results in tumour response and improved OS in
patients with liver metastases from carcinoid tumours (Rinke et al,
2009) and that patients with low-grade tumours and preserved
SSTR-2 and 5 expressions have better survival times while on
somatostatin analogues (Corleto et al, 2009). In future studies it
would be of interest to assess whether SSTR-2 expression does
correlate to outcome in patients treated with octreotide.
Recent evidence has shown interplay between SSTR signalling
and hypoxia, suggesting that the therapeutic efficacy of octreotide
may be at least, in part, explained by the downregulation of Hif-1a
transcriptional activity (Villaume et al, 2010). Hypoxia inducible
factor 1a, a master regulator of the hypoxic response, is a
transcription factor that controls the expression of downstream
proteins including, among the others, VEGF-A and Ca-IX, whose
role is crucial in securing survival advantage of tumour cells
in hypoxic conditions by promoting neovascular supply and
reducing intracellular acidosis (Giatromanolaki and Harris, 2001).
Although the importance of hypoxia has been studied in a number
of tumour types there has been a paucity of studies considering
hypoxia in GEP-NETs except in patients with pancreatic NETs
arising in a background of VHL syndrome. In this patient group, a
strong correlation has been demonstrated between HIF-1a, Ca-IX
and VEGF expression (Perigny et al, 2009; O’Toole et al, 2010).
Interestingly, although Hif-1a seems central in the progression of
pancreatic NETs, where the activation of the Hif-1a/Ca-IX
transcriptional programme associates with poor prognosis, the
expression of VEGF negatively correlates with tumour progression
(Couvelard et al, 2005). In our study, we identified Hif-1a but not
Ca-IX expression as a predictor of OS. Such difference with the
Couvelard study may be explained by the inherent differences in
the patient populations considered, including differing sample size,
the inclusion of patients with VHL disease as well as the lack of
multivariate screening of prognostic variables.
Interestingly, the pathogenic role of hypoxia is confirmed in
non-pancreatic GI-NETs, where Hif-1a is expressed homogenously
in both primaries and metastases (Arvidsson et al, 2010). In our
study, the majority of tumours displayed evidence of VEGF-A
expression, in keeping with the concept that GEP-NETs are highly
vascular tumours (Terris et al, 1998; Seo et al, 2000; Zhang et al,
2007; Arvidsson et al, 2010). Despite finding that both VEGF-A
and Hif-1a expressions correlated with the presence of liver
metastases, we did not demonstrate any association between
VEGF-A and OS. There is a lack of consensus in the literature
regarding the prognostic role of VEGF expression in NETs, with
some studies suggesting a prognostic role (Zhang et al, 2007),
whereas others refuting this (Takahashi et al, 2007; Kuiper et al,
2011). Moreover, in pancreatic NETs, VEGF-A expression and
microvascular count seem to paradoxically reduce with progressive
tumour de-differentiation (Scoazec, 2012) such that NETs with
lower microvessel density have a worse outcome (Marion-Audibert
et al, 2003). This may highlight a more complex functional role for
the VEGF family, where certain isoforms retain antivascular
properties (Albrecht et al, 2010). Another factor that may account
for the lack of association between VEGF-A levels and survival in
our study may be the relatively good prognosis of patients with
GEP-NETs, where 5-year survival figures range between 25 and
100% (Metz and Jensen, 2008; Modlin et al, 2008) even in the
presence of liver metastases. As the median survival in our cohort
was 8.8 years, with the majority of tumours being well
differentiated and early stage, we hypothesise that the stage and
grade distribution of our cohort may not be adequate to detect a
prognostic role for VEGF-A, whose expression seems to be
strongly stage and grade-dependant.
We confirmed that WHO grading based on Ki-67 proliferation
count was associated with a more aggressive disease course and
worse OS, confirming the association between tumour proliferation
and prognosis (Strosberg et al, 2009; Dimou et al, 2010; Panzuto
et al, 2012). This association translates into the clinical recom-
mendation of using Ki-67 expression to guide the administration of
systemic chemotherapy, based on the evidence that treatment-
induced benefits are minimal in tumours with Ki-67 index o1%
(O’Toole et al, 2010).
In conclusion, we have adopted a multivariate screening process
of tissue biomarkers to identify novel predictors of outcome
relating to hypoxia, angiogenesis and SSTR signalling. We have
shown that differential expression of SSTR-2 is predictive of OS in
patients with NETs, and that the presence of hypoxia as measured
by Hif-1a overexpression are potential predictors of clinical
outcome in patients with GEP-NETs.
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Figure 3. Derivation of an immunohistochemical prognostic signature
in GEPNETs based on Hif-1a and SSTR-2 expression status. Kaplan–
Meier survival curves show that for patients with preserved SSTR-2 and
low Hif-1a (i.e., no adverse prognostic factors, black line) median OS
was not reached after a median follow up of 8.8 years. Patients with
SSTR-2 loss and high Hif-1a expression (i.e., two adverse prognostic
factors, grey dotted line) had a median survival of only 4.2 years.
Patients with only one adverse prognostic factor (either SSTR-2 loss
or elevated Hif-1a expression, grey continuous line) had a median
OS of B10 years from diagnosis.
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We used this information to generate a coherent immunohis-
tochemical expression signature that combines the independent
prognostic information obtained from SSTR-2 status and Hif-1a
overexpression, and confirmed that this signature accurately
predicts prognosis independent of tumour stage and proliferation
status, allowing us to further refine survival prediction in a patient
population that is generally regarded as carrying a good prognosis.
We are limited by the need for a prolonged time span used for
patient accrual, during which radical changes in diagnosis and
management may have influenced survival outcomes. This was
dictated by the relative low incidence rates of GEP-NETs and the
long survival times that characterise the natural history of these
tumours and is a common limitation applying to most studies
investigating prognostic factors in this tumour type. In addition, it
would be important to ascertain whether our newly identified
prognostic signature can predict progression-free survival, a more
easily quantifiable survival endpoint in cancers with a relatively
indolent biological behaviour.
In future studies, it would be important to validate our findings
in an independent, larger patient cohort, considering treatment
regimens administered, which was incomplete in our cohort.
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